Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares fell as much as 21 percent in pre-market trading on July 9, 2026, before finding a floor near 74 dollars, after the company and partner AstraZeneca plc announced that their Phase 3 CARDIO-TTRansform trial evaluating Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy failed to meet its primary efficacy endpoint of reducing the composite outcome of cardiovascular mortality and recurrent cardiovascular clinical events through 140 weeks compared with placebo.

The failure was described as unexpected by Bank of America analyst Sachin Jain, who wrote that data came as a surprise “given we and investors hadn’t even debated likelihood of a primary endpoint miss,” and Stifel analyst Paul Matteis noted the only pre-readout question had been how eplontersen would compare to an already-approved competitor rather than whether it would succeed. Financial Times reporting indicates that peak Wainua sales expectations have been reset from approximately 6.5 billion dollars to around 4 billion dollars in the wake of the trial failure, reflecting the loss of the ATTR-CM opportunity that had been expected to become the dominant contributor to the franchise.

Ionis Pharmaceuticals shares traded within a session range of 73.99 to 86.74 dollars on volume of 2.14 million shares, close to the average, and the intraday low set a 14.7 percent decline from the session’s 52-week high, while AstraZeneca plc separately fell approximately 9 percent in London, marking the FTSE 100 pharmaceutical giant as the biggest constituent decliner on the index for the session. The read-across for the Carlsbad, California-based antisense oligonucleotide developer is materially negative in the near term, since Wainua royalties represented the fastest-growing partnered franchise on Ionis Pharmaceuticals’ commercial platform and the ATTR-CM indication had been widely expected to unlock a multi-fold revenue expansion beginning in 2027, and the ATTR-CM competitive landscape now consolidates further around Pfizer Inc. Vyndamax, Alnylam Pharmaceuticals, Inc. Amvuttra, and BridgeBio Pharma, Inc. Attruby without a new nucleic acid-based challenger.

What does the CARDIO-TTRansform trial failure actually mean for Ionis Pharmaceuticals’ pipeline strategy

The immediate strategic implication is that Ionis Pharmaceuticals has lost the single largest expected revenue expansion catalyst in its partnered portfolio for the second half of the decade. Wainua in the ATTR polyneuropathy indication generated 51 million dollars of global sales in the first quarter of 2026 and 11 million dollars of royalty revenue for Ionis Pharmaceuticals, and the trajectory had been building steadily following its 2023 FDA approval. The ATTR-CM opportunity was expected to deliver a substantially larger commercial base, given the cardiomyopathy patient population is more than an order of magnitude larger than the polyneuropathy population and given the pricing power that has been established by Pfizer Inc. Vyndamax at more than 6 billion dollars in 2025 sales.

The trial failure does not close the ATTR-CM chapter entirely. AstraZeneca plc and Ionis Pharmaceuticals disclosed that a prespecified subgroup analysis of patients treated with Wainua monotherapy showed fewer primary composite events compared with placebo, but the effect was not statistically significant, and the companies intend to present the complete dataset at the European Society of Cardiology Congress. That subgroup signal keeps open the theoretical possibility of a monotherapy-focused regulatory pathway or a redesigned confirmatory trial in patients not receiving background stabiliser therapy, but the commercial ceiling of any such indication would be materially lower than the full ATTR-CM label that had been contemplated.

The wider strategic implication is that Ionis Pharmaceuticals’ pipeline diversification thesis becomes more important, not less, as the Wainua contribution flattens. The company has been executing a deliberate transition from a royalty-heavy business anchored on Biogen Inc. Spinraza royalties toward a commercial-stage biotechnology operator with its own marketed medicines. The recent United States approval of TRYNGOLZA (olezarsen) for triglyceride reduction in familial chylomicronemia syndrome, the launch of DAWNZERA (donidalorsen) in hereditary angioedema, and the ongoing Phase 3 REVEAL trial of obudanersen in Angelman syndrome collectively represent the pipeline optionality that must now carry the equity story through the ATTR-CM disappointment.

Why did Wall Street analysts fail to price in even the possibility of a Wainua Phase 3 miss

The failure of the analyst community to hedge for a negative CARDIO-TTRansform outcome is analytically instructive. Bank of America analyst Sachin Jain’s public acknowledgement that the miss “comes as a surprise given we and investors hadn’t even debated likelihood of a primary endpoint miss” reflects a broader consensus that had converged on the assumption that Wainua would succeed. That assumption rested on three pillars. First, Wainua and Alnylam Pharmaceuticals, Inc.’s Amvuttra share the same underlying therapeutic principle of suppressing transthyretin protein production, and Alnylam Pharmaceuticals, Inc. had demonstrated success in the HELIOS-B trial in ATTR-CM. Second, Wainua had already been approved and commercially validated in ATTR polyneuropathy. Third, the CARDIO-TTRansform trial was the largest ATTR-CM trial ever conducted, enrolling 1,432 patients across 130 sites in 20 countries, which suggested statistical power sufficient to detect even modest treatment effects.

The failure of the primary endpoint despite these positive prior indicators highlights the limits of read-across analysis in complex late-stage cardiovascular trials. Antisense oligonucleotides and small interfering RNA therapies operate through mechanistically related but not identical pathways for reducing transthyretin, and the specific pharmacokinetic and pharmacodynamic profiles differ enough that clinical translation is not guaranteed. Trial design differences, including patient selection, background therapy composition, and endpoint definition, further complicate the mechanical translation of one programme’s results to another. The lesson for future large-scale trial design is that mechanistic proximity is not a substitute for programme-specific pivotal evidence.

The analyst consensus positioning was reflected in the sell-side price target trajectory heading into the release. H.C. Wainwright had raised its target on Ionis Pharmaceuticals to 130 dollars from 125 dollars on June 25, 2026, Goldman Sachs had raised its target to 75 dollars on June 24, 2026, and the aggregate consensus target across 26 analysts was 100.92 dollars, implying approximately 35.5 percent upside from the pre-announcement share price. That level of positive consensus positioning meant that the pre-print options market did not embed adequate downside protection, and the resulting share price move reflected both the fundamental Wainua reset and the technical unwinding of positions built on the assumption that the trial would succeed.

How does the trial design and stabilizer usage explain the divergence from Alnylam’s Amvuttra success

The trial design comparison between CARDIO-TTRansform and Alnylam Pharmaceuticals, Inc.’s HELIOS-B provides the most defensible mechanistic explanation for the divergent outcomes. In CARDIO-TTRansform, 57 percent of patients in each study arm were receiving a transthyretin stabiliser at baseline, and an additional 24 percent initiated stabiliser therapy during the trial. By the end of the trial, more than 80 percent of the CARDIO-TTRansform population had been exposed to stabiliser therapy alongside the study drug. By contrast, in HELIOS-B, 53 percent of patients received a stabiliser at some point during the trial. The compositional difference is substantial and directly relevant to the interpretation of the negative CARDIO-TTRansform primary endpoint result.

Stabilisers such as Pfizer Inc.’s Vyndamax (tafamidis) and BridgeBio Pharma, Inc.’s Attruby (acoramidis) work by preventing the misfolding of the transthyretin protein at the tetrameric level, which is a mechanistically upstream intervention relative to suppressing production of the protein itself. In a patient population already receiving background stabilisation, the incremental benefit of adding an additional protein-lowering therapy may be more difficult to detect statistically, particularly for outcome measures like cardiovascular mortality and event rates that are influenced by many independent factors. AstraZeneca plc’s disclosure that Wainua produced fewer events in the monotherapy subgroup, though without statistical significance, is consistent with this interpretation.

The strategic implication for Ionis Pharmaceuticals and AstraZeneca plc is that the residual clinical development opportunity for Wainua in ATTR-CM likely depends on identifying patient populations who cannot tolerate or do not respond adequately to stabiliser therapy. That is a substantially narrower commercial opportunity than the full ATTR-CM population, and any subsequent regulatory strategy would need to demonstrate that Wainua provides meaningful benefit in a well-defined stabiliser-inadequate or stabiliser-intolerant patient subgroup. The full CARDIO-TTRansform dataset scheduled for presentation at the European Society of Cardiology Congress will be the critical input into that strategic assessment.

What is the actual financial impact of the ATTR-CM revenue opportunity loss on Ionis’ long-term earnings model

The Financial Times reporting that Wainua peak sales expectations have been reset from approximately 6.5 billion dollars to around 4 billion dollars provides the anchor for the fundamental impact assessment. That 2.5 billion dollar reduction in peak sales reflects the loss of the majority of the ATTR-CM opportunity while retaining the fully commercialised ATTR polyneuropathy indication and preserving optionality on a narrower ATTR-CM label if the monotherapy subgroup analysis supports further development. For Ionis Pharmaceuticals specifically, the royalty economics on the collaboration determine the direct financial impact.

The Ionis Pharmaceuticals share of Wainua economics scales through both royalty payments on partner sales and milestone payments tied to development and commercial achievements. First-quarter 2026 Wainua royalties of 11 million dollars against approximately 51 million dollars of Wainua global sales imply a royalty rate in the low twenties percent for the ATTR polyneuropathy indication. Applying similar rate assumptions to the reduced Wainua peak sales expectation of 4 billion dollars implies peak annual royalty revenue of approximately 700 million to 900 million dollars for Ionis Pharmaceuticals at maturity, compared with the previously implied peak royalty revenue of approximately 1.2 billion to 1.5 billion dollars against a 6.5 billion dollar sales trajectory. The absolute reduction in expected long-term royalty revenue therefore approaches half a billion dollars per year at peak.

The near-term earnings impact is smaller. Wainua contributed 11 million dollars of royalty revenue in the first quarter of 2026 alongside 18 million dollars in joint development revenue, representing a meaningful but not dominant share of Ionis Pharmaceuticals’ total revenue of approximately 246 million dollars in the quarter. The most consequential impact on the near-term earnings model is the removal of milestone payments that AstraZeneca plc would have been expected to trigger upon successful Phase 3 completion and subsequent ATTR-CM approvals. Those milestone payments were expected to represent several hundred million dollars of non-dilutive capital over the coming quarters, and their removal materially changes the internal cash flow trajectory that Ionis Pharmaceuticals had been modelling for pipeline investment.

Why does the Angelman syndrome REVEAL trial and TRYNGOLZA launch matter more now than ever for the IONS thesis

With the Wainua expansion story now materially reset, the remaining Ionis Pharmaceuticals pipeline and commercial trajectory must carry the equity story. TRYNGOLZA (olezarsen) received FDA approval in mid-2026 for reducing triglycerides in adults with familial chylomicronemia syndrome and acute pancreatitis, and the commercial team infrastructure built for that launch is scaling into the broader olezarsen severe hypertriglyceridemia opportunity. Peak sales for TRYNGOLZA and DAWNZERA (donidalorsen) collectively have been projected to exceed 500 million dollars each at maturity, and the combined marketed portfolio revenue trajectory now becomes the anchor of the near-term commercial thesis.

The REVEAL Phase 3 trial of obudanersen in Angelman syndrome is the highest-value clinical readout on the Ionis Pharmaceuticals calendar for the coming 18 to 24 months. Ionis Pharmaceuticals completed pediatric cohort enrollment in the pivotal REVEAL trial in early July 2026, and the pivotal readout will be a substantial value inflection point given the unmet medical need in Angelman syndrome and the absence of currently approved disease-modifying therapies for the indication. A successful REVEAL outcome would deliver a new commercial franchise that could partially offset the Wainua ATTR-CM revenue loss, and it would validate the Ionis Pharmaceuticals antisense platform in a new indication category.

The broader partnered pipeline also acquires greater weight. Zilganersen for Alexander disease has been licensed to Recordati S.p.A. for ex-United States rights in an agreement announced on June 25, 2026, and GSK plc’s bepirovirsen has delivered positive Phase 3 pivotal data for chronic hepatitis B. Each of these programmes carries development and commercial milestone economics and royalty streams that will contribute to Ionis Pharmaceuticals’ revenue trajectory in the coming years, and their strategic value increases in the context of the Wainua reset. The composition of Ionis Pharmaceuticals’ business model is therefore more balanced across multiple partnered and internal programmes than the market had been valuing prior to today, and that composition should support a more resilient long-term revenue floor even at the reduced trajectory implied by the peak sales reset.

How does the ATTR-CM competitive landscape reset benefit Pfizer, Alnylam, and BridgeBio at Ionis’ expense

The ATTR-CM market had been widely expected to become a genuinely competitive four-player therapeutic area with Pfizer Inc. Vyndamax, Alnylam Pharmaceuticals, Inc. Amvuttra, BridgeBio Pharma, Inc. Attruby, and AstraZeneca plc / Ionis Pharmaceuticals, Inc. Wainua all commanding meaningful market share. The CARDIO-TTRansform failure removes the anticipated fourth entrant from that competitive dynamic, and the practical outcome is that the ATTR-CM commercial opportunity, which STAT News has valued at more than 15 billion dollars at peak, is now split among a smaller number of participants. Each of the three incumbents captures a larger share of that opportunity than had been contemplated 24 hours ago.

Alnylam Pharmaceuticals, Inc. is the clearest beneficiary from the trial failure. Amvuttra shares the closest mechanistic profile with Wainua, in that both are designed to reduce transthyretin protein production, and Amvuttra had been widely expected to face direct commercial competition from Wainua once the ATTR-CM approval was secured. Alnylam Pharmaceuticals, Inc. shares rose approximately 17.5 percent in pre-market trading on July 9, 2026, reflecting the market’s revised assessment of Amvuttra’s competitive position and its ability to consolidate the protein-lowering nucleic acid segment of the ATTR-CM market without a direct competitor from a comparable mechanistic class. BridgeBio Pharma, Inc. Attruby and Pfizer Inc. Vyndamax also benefit as the stabiliser mechanism retains a monopoly on that pharmacological pathway.

The read-across for the broader antisense oligonucleotide therapeutic class is more nuanced. The Wainua failure was specific to the ATTR-CM indication and the CARDIO-TTRansform trial design rather than a fundamental breakdown of antisense chemistry or mechanism of action. Ionis Pharmaceuticals’ own broader antisense portfolio, including TRYNGOLZA, DAWNZERA, obudanersen, and the partnered pipeline, has not been directly impacted by the CARDIO-TTRansform outcome. However, the failure will inevitably influence how investors weight the probability of success for other late-stage antisense programmes targeting cardiovascular endpoints, and any subsequent trial failure across the class would compound the current re-evaluation of antisense cardiovascular development risk.

What are the strategic options available to Ionis and AstraZeneca after the CARDIO-TTRansform disappointment

The most immediate strategic decision facing Ionis Pharmaceuticals and AstraZeneca plc is how to characterise and communicate the residual clinical development opportunity for Wainua in ATTR-CM. The prespecified monotherapy subgroup analysis provides a directional basis for arguing that Wainua may deliver benefit in patients who are not receiving background stabiliser therapy. Presenting the full dataset at the European Society of Cardiology Congress will allow the medical community and regulatory agencies to evaluate the totality of evidence, and the response from that presentation will shape whether a targeted follow-on trial in the stabiliser-inadequate or stabiliser-intolerant population is worth the additional investment.

The regulatory pathway options for Wainua in ATTR-CM include continuing to develop the indication through an additional pivotal trial focused on a defined subpopulation, pursuing a narrower label based on the current CARDIO-TTRansform dataset if the regulatory agencies conclude the subgroup evidence is sufficient, or discontinuing the ATTR-CM development programme entirely and focusing resources on the existing ATTR polyneuropathy indication and other pipeline priorities. Each option carries different capital requirements, timelines, and commercial upside, and the decision framework will depend heavily on the additional insights that emerge from the full dataset presentation.

The strategic communication challenge for AstraZeneca plc is broader than the specific Wainua programme. The company has communicated a target of approximately 80 billion dollars in annual revenue by 2030, and Wainua had been one of a group of expected launches that would contribute to that target. The Wainua reset removes a meaningful contribution to that goal, and AstraZeneca plc will need to reassure investors that the remaining launch portfolio can deliver the aggregate revenue growth on the expected timeline. The AstraZeneca plc share price reaction of approximately 9 percent decline reflects that broader strategic overhang, and the recovery trajectory for the AstraZeneca plc equity will depend on the delivery cadence across the remaining pipeline over the coming quarters.

Key takeaways on what the Wainua failure means for antisense biotech, cardiovascular RNA drugs, and IONS investors

• Ionis Pharmaceuticals, Inc. shares fell approximately 21 percent in pre-market trading on July 9, 2026, before finding a floor near 74 dollars, after the CARDIO-TTRansform Phase 3 trial of Wainua (eplontersen) failed to meet its primary efficacy endpoint of reducing cardiovascular mortality and recurrent cardiovascular events over 140 weeks in transthyretin-mediated amyloid cardiomyopathy.
• Financial Times reporting indicates that Wainua peak sales expectations have been reset from approximately 6.5 billion dollars to around 4 billion dollars, a 2.5 billion dollar reduction that reflects the loss of the majority of the ATTR-CM opportunity while preserving the existing ATTR polyneuropathy indication.
• The trial failure caught Wall Street analysts by surprise, with Bank of America analyst Sachin Jain acknowledging that investors “hadn’t even debated likelihood of a primary endpoint miss” and Stifel analyst Paul Matteis noting that the only pre-readout question had been how eplontersen would compare to Alnylam Pharmaceuticals, Inc.’s Amvuttra.
• Trial design and background therapy composition explain much of the divergence from Alnylam Pharmaceuticals, Inc. HELIOS-B success, with 57 percent of CARDIO-TTRansform patients receiving a transthyretin stabiliser at baseline and an additional 24 percent initiating stabiliser therapy during the trial, compared with 53 percent stabiliser exposure at some point in the Alnylam Pharmaceuticals, Inc. trial.
• A prespecified subgroup analysis of Wainua monotherapy patients showed fewer primary composite events compared with placebo but did not reach statistical significance, keeping open the theoretical possibility of a targeted regulatory pathway for stabiliser-inadequate or stabiliser-intolerant patients.
• Ionis Pharmaceuticals’ near-term financial impact is smaller than the peak sales reset suggests, with first-quarter 2026 Wainua royalty revenue of 11 million dollars representing a meaningful but not dominant share of quarterly revenue, though several hundred million dollars of expected AstraZeneca plc milestone payments tied to Phase 3 success and subsequent ATTR-CM approvals are now removed from the model.
• Alnylam Pharmaceuticals, Inc., BridgeBio Pharma, Inc., and Pfizer Inc. emerge as clear beneficiaries of the trial failure, and Alnylam Pharmaceuticals, Inc. shares rose approximately 17.5 percent in pre-market trading as Amvuttra consolidates the protein-lowering nucleic acid segment of the ATTR-CM market without a direct nucleic acid-based competitor.
• The remaining Ionis Pharmaceuticals pipeline, anchored by TRYNGOLZA (olezarsen) and DAWNZERA (donidalorsen) commercial launches, the pivotal REVEAL Phase 3 trial of obudanersen in Angelman syndrome, and partnered programmes with GSK plc, Recordati S.p.A., and Biogen Inc., now carries greater strategic weight for the equity thesis.
• AstraZeneca plc’s decline of approximately 9 percent in London trading, making the company the biggest constituent decliner on the FTSE 100 for the session, reflects the broader strategic overhang on the target of approximately 80 billion dollars in annual revenue by 2030 and the removal of Wainua’s expected contribution from that trajectory.
• The full CARDIO-TTRansform dataset scheduled for presentation at the European Society of Cardiology Congress will be the critical input into the strategic decision on whether to pursue further Wainua ATTR-CM development, and the outcome of that decision will shape both the Ionis Pharmaceuticals and AstraZeneca plc equity narratives over the coming quarters.